CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP) Files An 8-K Results of Operations and Financial Condition
Item 2.02.
|
Results of Operations and Financial Condition. |
Corbus Pharmaceuticals Holdings, Inc. (the Company) issued a
press release on May 9, 2017, disclosing financial information
and operating metrics for its fiscal quarter ended March 31,
2017, and discussing its business outlook. A copy of the Companys
press release is attached as Exhibit 99.1 to this Current Report
on Form 8-K and is incorporated herein by reference.
| Item 7.01. | Regulation FD Disclosure. |
See Item 2.02 Results of Operations and Financial Condition
above.
The information in this Current Report on Form 8-K under Items
2.02 and 7.01, including the information contained in Exhibit
99.1, is being furnished to the Securities and Exchange
Commission, and shall not be deemed to be filed for the purposes
of Section 18 of the Securities Exchange Act of 1934 or otherwise
subject to the liabilities of that section, and shall not be
deemed to be incorporated by reference into any filing under the
Securities Act of 1933 or the Securities Exchange Act of 1934,
except as shall be expressly set forth by a specific reference in
such filing.
| Item 9.01. | Financial Statements and Exhibits. |
(d) The following exhibit is furnished with this report:
| Exhibit No. | Description | |
| 99.1 |
Press Release issued by Corbus Pharmaceuticals Holdings, Inc. dated May 9, 2017. |
About CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP)
Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare or uncommon chronic and serious inflammatory and fibrotic diseases. The Company’s segment is developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases. Its product, Resunab, is a synthetic oral endocannabinoid-mimetic drug that is designed to resolve chronic inflammation and halt fibrotic processes without causing immunosuppression. Resunab is being evaluated in approximately three separate Phase II studies for the treatment of cystic fibrosis, systemic sclerosis and skin-predominant dermatomyositis. The United States Food and Drug Administration has granted Resunab Orphan Drug Designation, as well as Fast Track Status, for both cystic fibrosis and systemic sclerosis. Resunab is in Phase II clinical stage for the treatment of Systemic Lupus Erythematosus. CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP) Recent Trading Information
CORBUS PHARMACEUTICALS HOLDINGS, INC. (NASDAQ:CRBP) closed its last trading session 00.00 at 6.20 with 647,721 shares trading hands.